Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Norastemizole Sepracor.

K A Bachmann1

  • 1University of Toledo, College of Pharmacy, 2801 W Bancroft Street, Toledo, OH 43606, USA. kbachma@utnet.utoledo.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[New guidelines on chronic pancreatitis : interdisciplinary treatment strategies].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2013
Same author

Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise.

Current drug metabolism·2006
Same author

Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.

Journal of clinical pharmacology·2001
Same author

The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions.

Current drug metabolism·2001
Same author

Differential kinetics of phenytoin in elderly patients.

Drugs & aging·1999
Same author

Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.

Clinical pharmacology and therapeutics·1999
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Norastemizole, a potent non-sedating histamine H1 antagonist, shows rapid allergy relief with no cardiotoxicity. This active metabolite of Hismanal is expected to file for FDA approval soon.

Area of Science:

  • Pharmacology
  • Allergology

Background:

  • Norastemizole is a novel histamine H1 antagonist developed for non-sedating allergy treatment.
  • It is an active metabolite of astemizole (Hismanal).

Purpose of the Study:

  • To evaluate the efficacy and safety of norastemizole for allergic rhinitis.
  • To position norastemizole as a potent, non-sedating allergy therapeutic with a rapid onset of action.

Main Methods:

  • Phase III clinical trials for seasonal allergic rhinitis.
  • Assessment of histamine-induced wheal and flare responses post-administration.
  • Evaluation of cardiotoxicity and drug interaction profiles.

Main Results:

  • Norastemizole demonstrates 13- to 16-fold greater H1 antagonist potency than astemizole.

Related Experiment Videos

  • Significant reduction in histamine-induced wheal and flare responses within 30 minutes of a 25 mg oral dose.
  • Lack of observed cardiotoxicity or drug interactions that increase arrhythmia risk.

    • Conclusions:

    • Norastemizole is a highly potent, non-sedating H1 antagonist with rapid onset of action.
    • Its favorable safety profile, particularly the absence of cardiotoxicity, distinguishes it from other allergy treatments.
    • Anticipated FDA approval and strong market potential for allergic rhinitis treatment.